American Assn of Blood Banks
The AABB is a United States-based professional body and standards organization that was founded in 1947 as the American Association of Blood Banks. The organization is now international with members in 80 countries and has taken on a broader scope to include all of transfusion medicine as well as cellular therapies, specifically ones based on hematopoietic stem cells. In 2005 the organization changed its name to AABB to reflect the changes in scope and operations.
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of American Assn of Blood Banks
Names of Lobbyists
Firm Hired Amount American Assn of Blood Banks $124,800
Most Frequently Disclosed Lobbying Issues
- Fed Budget & Appropriations,
- Medical Research & Clin Labs,
- Disaster & Emergency Planning,
- Health Issues,
- Medicare & Medicaid,
- Government Issues
Most Frequently Disclosed Bills
Bill No. Title S.3295 Department of Labor Appropriations Act, 2013 H.R.6118 Taking Essential Steps for Testing Act of 2012 S.1599 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012 H.R.2146 DATA Act H.R.3070 Department of Education Appropriations Act, 2012 S.1789 21st Century Postal Service Act of 2011 S.3686 Department of Labor Appropriations Act, 2011
RegulationsMentioned in 6 dockets; Submitted to 1 docket
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "American Assn of Blood Banks" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for American Assn of Blood Banks
Mentions in Document Text
View all mentions data for American Assn of Blood Banks
- Toggle 3 FDA Draft Guidance for Industry: Implementation of Acceptable Abbreviated Donor History Questionnaire and Accompanying Materials for Use in Screening Frequent Donors of Blood and Blood Components; Availability 2011
- Toggle 2 VA 2012 Notices Requesting Comments 2012
- Toggle 2 FDA Draft Guidance for Industry: Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma; Availability 2011
- Toggle 2 FDA Pediatric Studies of Sodium Nitroprusside Conducted in Accordance with Section 409 I of the Public Health Service Act 2012
- Toggle 1 FDA Draft Guidance for Industry and FDA Staff: Commercially Distributed In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Frequently Asked Questions; Availability 2011
- Toggle 1 FDA Applications for Food and Drug Administration Approval to Market a New Drug; Revision of Postmarketing Reporting Requirements--Discontinuance 2011